Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan (PKDL)
A Prospective Cohort Study on the Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis After Treatment for Primary Visceral Leishmaniasis in South Sudan
Sponsor: Drugs for Neglected Diseases
A observational or N/A phase clinical study on Leishmaniasis and Leishmaniasis, Visceral, this trial is completed. The trial is conducted by Drugs for Neglected Diseases and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Oct 2023 — Jul 2024 [monthly]
Recruiting
-
Sep 2022 — Oct 2023 [monthly]
Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Drugs for Neglected Diseases
- Epicentre
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Medecins Sans Frontieres, Netherlands
For direct contact, visit the study record on ClinicalTrials.gov .